Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 1:59 PM
Ignite Modification Date:
2025-12-24 @ 1:59 PM
NCT ID:
NCT00899795
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Meets 1 of the following criteria:
* Diagnosis of acute myeloid leukemia or myelodysplastic syndromes and requires bone marrow aspiration/biopsy for clinical purposes
* Primary or secondary disease
* Diagnosis of Fanconi anemia by positive mitomycin C test (age 5 to 55 years)
* Received prior chemotherapy containing any of the following alkylating agents: mechlorethamine, chlorambucil, cyclophosphamide, melphalan, busulfan, or topoisomerase inhibitors
* Healthy volunteer (age 18 and over), meeting the following criteria:
* CBC normal
* WBC \> 1,000/mm³
* Hemoglobin \> 10 g/dL
* Platelet count \> 70,000/mm³
* No bone marrow metastases
* No evidence of non-hematopoietic malignancy
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* No clinical signs and symptoms of acute or subacute infection (viral, bacterial, or fungal infection)
* No allergy to lidocaine or xylocaine
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* More than 6 months since prior cytotoxic or immunosuppressive agents
* No prior extensive pelvic radiotherapy (\> 20 Gy)
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
5 Years
Maximum Age:
120 Years
Study:
NCT00899795
Study Brief:
Protocol Section:
NCT00899795